| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Technology development and licensing revenue | |||||||||
500 | 500 | 500 | - | - | - | - | - | - | - |
Licensing revenue | |||||||||
- | - | - | 500 | 500 | 500 | 500 | - | 2,000 | - |
Operating expenses: | |||||||||
Research and development | |||||||||
13,065 | 11,865 | 13,078 | 14,623 | 14,659 | 14,969 | 9,364 | 15,770 | 19,863 | 14,714 |
General and administrative | |||||||||
8,000 | 9,699 | 5,889 | 6,526 | 6,686 | 8,860 | 6,547 | 6,372 | 5,154 | 4,922 |
Acquisition costs | |||||||||
- | - | - | - | - | 1,385 | - | - | - | - |
Total operating expenses | |||||||||
21,065 | 21,565 | 18,968 | 21,149 | 21,346 | 25,215 | 15,911 | 22,142 | 25,018 | 19,637 |
Loss from operations | |||||||||
-20,565 | -21,065 | -18,468 | -20,649 | -20,846 | -24,715 | -15,411 | -22,142 | -23,018 | -19,637 |
Other income (expense): | |||||||||
(Loss) gain from change in valuation of earn-out milestone liability | |||||||||
3,189 | 3,630 | - | - | - | - | - | - | - | - |
Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments | |||||||||
-400 | - | - | - | - | - | - | - | - | - |
Impairment of in-process research and development | |||||||||
- | 4,510 | - | - | - | - | - | - | - | - |
Gain from change in earn-out milestone liability | |||||||||
- | - | 649 | - | - | - | - | - | - | - |
(Loss) gain from change in valuation of earn-out milestone liability | |||||||||
- | - | - | - | - | 213 | - | - | - | - |
Loss from valuation of common stock warrant liability | |||||||||
- | - | - | - | -61 | 204 | 8,090 | -4,117 | 81 | 573 |
(Loss) gain from valuation of common stock warrant liability | |||||||||
- | - | - | - | - | 204 | 8,090 | -4,117 | 81 | 573 |
Gain from change in valuation of earn-out milestone liability | |||||||||
- | - | - | 733 | - | - | - | - | - | - |
Loss from change in valuation of earn-out milestone liability | |||||||||
- | - | - | - | -257 | - | - | - | - | - |
Impairment of in-process research and development | |||||||||
- | - | 2,520 | 1,444 | - | - | - | - | - | - |
Investment income | |||||||||
500 | 353 | 26 | 26 | 63 | 77 | -12 | 52 | - | 32 |
Investment income, net | |||||||||
- | - | - | - | - | - | - | - | 174 | - |
Interest expense | |||||||||
1,393 | 712 | 91 | 722 | 1,357 | 1,326 | 915 | 359 | 501 | - |
Interest expense | |||||||||
- | - | - | - | - | - | - | - | - | 31 |
Other income | |||||||||
0 | 0 | 2 | 3 | -1 | 51 | -2 | -1 | 42 | 244 |
Total other income (expense), net | |||||||||
1,897 | -1,237 | -1,933 | -1,403 | -1,614 | -779 | 7,160 | -4,425 | -203 | 818 |
Net loss before income tax benefit | |||||||||
-18,668 | -22,302 | -20,402 | - | - | - | - | - | - | - |
Income tax benefit | |||||||||
-1,816 | -10,419 | - | - | - | - | - | - | - | - |
Net loss | |||||||||
-16,851 | -11,883 | -20,402 | -22,053 | - | -25,494 | -8,251 | -26,568 | - | -18,818 |
Deemed dividend related to warrant modification | |||||||||
- | - | -345 | 0 | - | - | - | - | - | - |
Non-cash deemed dividend from beneficial conversion feature on convertible preferred stock | |||||||||
- | - | - | - | - | - | 4,601 | - | - | - |
Net loss attributable to common shareholders | |||||||||
- | - | -20,747 | -22,053 | -22,461 | -25,494 | -12,852 | -26,568 | -23,222 | - |
Net loss per common share - Basic and diluted | |||||||||
-0.77 | -0.68 | -2.72 | -11.89 | -1.03 | -1.38 | -0.95 | -3.44 | -5.00 | -1.52 |
Weighted average common shares outstanding - Basic and diluted | |||||||||
21,832 | 17,582 | 7,627 | 1,854 | 21,813 | 18,472 | 13,540 | 7,730 | 4,648 | 12,375 |